The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
The Chemours CompanyNYSE: CC
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $80M fell 13.0% year over year, ahead of the -29.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, up 0.6 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -13.0% holds above the trailing-twelve-month pace of -29.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 340M USD
- Year-over-year change
- +13.0%
- 4-year CAGR
- +1.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 340M | +13.0% |
| FY2024 | 2024-12-31 | 301M | -2.0% |
| FY2023 | 2023-12-31 | 307M | +5.5% |
| FY2022 | 2022-12-31 | 291M | -8.2% |
| FY2021 | 2021-12-31 | 317M | — |
Depreciation & Amortization vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 depreciation & amortization of $238M is the 8th largest of the 19 companies compared; the peer median is $185.5M.
- Its year-over-year change of -29.2% is the 18th highest of 19, against a peer median of +3.8%.
- Depreciation & amortization amounts to 4.1% of revenue for CC, versus a peer median of 7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.83B | +2.7% | -3.6% | 10.8% | |
| LTM Jun 2026 | $1.54B | +0.8% | +3.9% | 12.3% | |
| LTM Sep 2026 | $1.44B | +3.6% | +3.1% | 4.5% | |
| LTM Sep 2026 | $1.16B | -0.4% | +3.7% | 10.1% | |
| LTM Jun 2026 | $948M | -2.2% | -6.6% | 9.5% | |
| LTM Jun 2026 | $538M | +8.9% | +1.7% | 3.3% | |
| LTM Jun 2026 | $303M | +5.2% | -0.9% | 5.9% | |
| LTM Jun 2026 | $238M | -29.2% | +5.3% | 4.1% | |
| LTM Sep 2026 | $196.64M | +18.2% | +16.2% | 12.9% | |
| LTM Jun 2026 | $191M | -33.2% | -0.6% | 10.4% | |
| LTM Jun 2026 | $180M | +19.2% | +1.8% | 5.0% | |
| LTM Sep 2026 | $169.5M | +11.7% | -2.1% | 4.9% | |
| LTM Aug 2026 | $138.46M | -22.6% | +6.7% | 3.9% | |
| LTM Mar 2026 | $133.1M | +4.1% | +7.7% | 7.4% | |
| LTM Sep 2026 | $101.38M | +13.4% | +5.1% | 5.0% | |
| LTM Jun 2026 | $80.68M | +19.1% | +4.0% | 10.7% | |
| LTM Mar 2026 | $65.17M | -28.0% | -0.2% | 8.0% | |
| LTM Jun 2026 | $62.19M | +2.1% | +5.2% | 3.7% | |
| LTM Mar 2026 | $9.89M | +10.8% | -2.6% | 9.0% | |
| Peer median (excluding CC) | $185.5M | +3.8% | +2.5% | 7.7% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| Deferred Income Tax | (77M) | 20M | (158M) | (27M) | 64M |
| Stock-Based Compensation | 34M | 27M | 19M | 15M | 21M |
| Change in Working Capital | 21M | (103M) | 620M | (1.05B) | 178M |
| Accounts Receivables | (225M) | 91M | 0 | (152M) | 106M |
| Inventory | (210M) | (294M) | 58M | (146M) | (106M) |
| Accounts Payables | 281M | 105M | (72M) | (9M) | (165M) |
| Other Working Capital | 175M | (5M) | 634M | (745M) | 343M |
| Other Non-Cash Items | (89M) | (58M) | 6M | 44M | 47M |
| Operating Cash Flow | 814M | 755M | 556M | (633M) | 264M |
| Capital Expenditures | (277M) | (307M) | (370M) | (360M) | (213M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 7M |
| Purchases of Investments | (12M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 509M | 23M | 141M | 7M | 0 |
| Investing Cash Flow | 220M | (284M) | (229M) | (353M) | (206M) |
| Debt Repayment | (208M) | (80M) | 393M | 95M | (61M) |
| Common Stock Issued | 0 | 0 | 0 | 9M | 0 |
| Common Stock Repurchased | (173M) | (495M) | (69M) | 0 | (1M) |
| Dividends Paid | (164M) | (154M) | (149M) | (148M) | (78M) |
| Other Financing Activities | (9M) | 43M | 16M | 8M | 14M |
| Financing Cash Flow | (554M) | (686M) | 172M | (36M) | (126M) |
| Effect of Forex Changes | (34M) | (32M) | 4M | (22M) | 27M |
| Net Change in Cash | 446M | (247M) | 503M | (1.04B) | (41M) |
| Free Cash Flow | 537M | 448M | 186M | (993M) | 51M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.